18 CAMPUS BLVD., NEWTOWN SQUARE, PA
ArriVent BioPharma Files Prospectus Supplement for $250 Million ATM Program
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
To Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results
Arrivent Unveils Firmonertinib Study Results for EGFR Mutant Lung Cancer at 2025 Lung Cancer Conference
Reports Second Quarter 2025 Financial Results
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership